PCM
FBRX icon

Pinz Capital Management’s Forte Biosciences FBRX Stock Holding History

Pinz Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-112
Closed -$94K – 227
2021
Q2 		$94K Buy
+112
New +$101K 0.03% 262

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Pinz Capital Management's FBRX Position: Q3 2021 in Review

Pinz Capital Management sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 112 shares — an estimated $94K sold.

Pinz Capital Management first reported a position in FBRX in Q2 2021 and held it in 1 quarter. The position peaked at $94K in Q2 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • Pinz Capital Management reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 112 Forte Biosciences shares in Q3 2021, an estimated $94K.
  • Pinz Capital Management first reported a position in Forte Biosciences in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Forte Biosciences position peaked at $94K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.